Results: Current asthma was identified in 75 (34%) of 218 HIV-infected participants and 38 (25%) of 152 HEU participants (adjusted PR, 1.33; P 5 .11). The prevalence of obstructive disease did not differ by HIV status. Reversibility was less likely in HIV-infected youth than in HEU youth (17/183 [9%] vs 21/126 [17%]; adjusted PR, 0.47; P 5 .020) overall and among just those with obstructive PFT results (adjusted PR, 0.46; P 5 .016). Among HIV-infected youth with current asthma, serum IgE levels were inversely correlated with CD8 T-cell counts and positively correlated with eosinophil counts and not associated with CD4 T-cell counts. HIV-infected youth had lower association of specific IgE levels to several inhalant and food allergens compared with HEU participants and significantly lower CD4/CD8 T-cell ratios (suggesting immune imbalance). Conclusion: Compared with HEU youth, HIV-infected youth demonstrated decreased reversibility of obstructive lung disease, which is atypical of asthma. This might indicate an early stage of chronic obstructive pulmonary disease. Follow-up into adulthood is warranted to further define their pulmonary outcomes. (J Allergy Clin Immunol 2017;140:1101-11.)
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Within the past decade, there have been several reports of a higher burden of asthma in HIV-infected adults [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] and children. [13] [14] [15] [16] [17] [18] [19] Data supporting this claim in children have used asthma medication history, physician examination and diagnosis, and medical chart review by medical personnel. The diagnosis of asthma in these studies lacked objective assessments of lung function. In the absence of objective measures, there is concern that asthma might be overdiagnosed in children. There might be a bias toward labeling HIV-infected children with respiratory symptoms as asthmatic, resulting in overtreatment with bronchodilators and asthma controller medications.
The possibility of misclassification of respiratory disease in HIV-infected participants was raised by Gingo et al 6 in HIVinfected adults. They compared lung function in HIV-infected adults with a diagnosis of asthma with lung function in those without asthma. They found that HIV-infected patients with asthma were more likely to have lung disease and less likely to have reversible airway obstruction.
Nonreversible airway obstruction is not consistent with the definition of asthma, which is characterized by obstructive pulmonary airflow reversible after bronchodilator treatments. Gingo et al 8, 9 postulated that the abnormal pulmonary function represents a complex syndrome of asthma and chronic obstructive pulmonary disease (COPD). Recently, several reports and editorials have appeared that describe an asthma-COPD overlap syndrome [20] [21] [22] [23] [24] [25] with mixed elements of both asthma and COPD and lack of reversibility. The cause of this syndrome is unknown and has been associated with adult HIV infection and lack of antiretroviral therapy. 6 In this report we present the results of a large multicenter study of respiratory disease and lung function in youth 10 to 21 years of age born to HIV-infected mothers. One distinct advantage of this pediatric observational study is that it includes an HIV-exposed uninfected (HEU) cohort as a comparison group to HIV youth. We defined asthma from chart review coded by using Medical Dictionary for Regulatory Activities (MedDRA) physician diagnosis, self-report asthma questionnaires, and pulmonary function tests (PFTs). In addition, we evaluated immune imbalance as a possible mechanism of chronic inflammation causing this disease (see the Introduction section in this article's Online Repository at www.jacionline.org). 13, 15, 26 
METHODS

Study population
HIV-infected and HEU youth enrolled in the Adolescent Master Protocol of the Pediatric HIV/AIDS Cohort Study (PHACS) were recruited for enrollment in this pulmonary substudy at 13 clinical sites. 17 Participants were excluded if they could not follow instructions for PFTs, had a known history of cardiac arrhythmia and/or hypertension, were pregnant, or gave birth within the last 6 weeks. Based on assumptions of the prevalence of asthma in HEU participants, we determined a priori the sample size necessary to have 80% power to detect a 13% increase in asthma in HIV-infected compared with HEU youth.
All aspects of this research study were approved by the Baylor College of Medicine Institutional Review Board, the Harvard T.H. Chan School of Public Health, and each participating clinical site. Permission of parents or legal guardians was obtained for youth (<18 years of age) on informed consent forms approved by local institutional review boards and the Harvard T.H. Chan School of Public Health. Assent of youth less than 18 years of age was obtained, when appropriate.
Outcome measures
The outcome measures were a history of ever having asthma, current asthma, ever having other pulmonary diseases, current pulse oximetry results, and current PFT results. The definitions for asthma and PFT classifications were developed based on recommendations from 2 study pulmonologists (M.K. and A.A.C.).
Asthma and other pulmonary diseases
Diagnoses of asthma and other pulmonary diseases were defined by using 5 questionnaires administered at entry and/or clinical diagnoses abstracted from the medical chart during the previous participant's enrollment in the Pediatric AIDS Clinical Trials Group 219C study and PHACS Adolescent Master Protocol. 17 The questionnaires used to define asthma status were as follows: 1, a questionnaire for other pulmonary diseases 27 ; 2, the Child Asthma Control Test for children 4 to 11 years old 28 ; 3, the Asthma Control Test for teens 12 years and older 29 ; 4, the abbreviated National Health and Nutrition Examination Survey Questionnaire for Asthma 30 ; and 5, an asthma history questionnaire designed by the study pulmonologists. Clinical diagnoses were coded into MedDRA by data management center personnel. MedDRA-coded clinical events were reviewed, and all preferred terms indicative of asthma and other pulmonary complications were identified within our study population.
The definitions of ''ever having asthma'' and ''current asthma'' provided in Table E1 in this article's Online Repository at www.jacionline.org are based on data from questionnaires, medication use, and diagnoses abstracted from the clinical chart. The definition of medication use indicative of asthma diagnosis is contained in Table E1 . Based on chart review, participants were identified as ''current asthma medication users'' if they received montelukast with albuterol, levalbuterol, or ipratropium or an inhaled corticosteroid in the past year (see Table E2 in this article's Online Repository at www.jacionline.org).
PFTs
PFTs were performed before and after bronchodilation with albuterol inhalation. Flow-loop (3-5 repeats) PFTs for each participant were evaluated centrally by 2 pediatric pulmonologists blinded to HIV status to determine whether the PFTs were acceptable by using American Thoracic Society criteria. 31 Based on raw spirometric data, predicted values were calculated centrally as the percentage of normal values based on age-sex-race/ ethnicity-adjusted reference values in healthy children from Hankinson et al. 32 Results of the PFTs allowed participants to be assigned to one of 4 mutually exclusive groups:
1. obstructive only, FEV 1 less than 80%, or FEV 1 /forced vital capacity (FVC) ratio of less than 80%, or forced expiratory flow, midexpiratory phase of less than 65%; 2. restrictive only, FVC of less than 80% and FEV 1 /FVC ratio of 80% or greater; 3. obstructive 1 restrictive, FVC of less than 80% and FEV 1 /FVC ratio of less than 80%; and 4. normal, not restrictive or obstructive.
The 12% bronchodilator response cutoff point that best identified asthma in adults has been questioned for accuracy in children. In a series of studies, the proposed cutoff point for pediatric patients ranged from 9% to 10.7%.
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Therefore we chose to define reversibility as an FEV 1 increase of greater than 10% after bronchodilation as the closest approximation.
Oxygen saturation of blood
Pulse oximetry (oxygen saturation) measured on breathing room air was conducted to determine oxygen saturation of blood (> _95% oxygen saturation was considered normal).
Total and specific serum IgE levels
Total and allergen-specific IgE levels (15 allergens) were measured in vitro in serum samples by using the US Food and Drug Administration-cleared, Phadia ImmunoCAP system in the Clinical Laboratory Improvement Amendments (CLIA)-licensed, College of American Pathologists (CAP)-accredited Quest Diagnostics laboratory facility in Baltimore, Maryland. [36] [37] [38] This assay system is a fully automated fluoroenzyme immunoassay method. For additional description of total and specific serum IgE levels, see Table  E3 in this article's Online Repository at www.jacionline.org.
Urinary cotinine
Urine specimens were assayed for nicotine, cotinine, 3-OH-cotinine, nornicotine, norcotinine, and anabasine by using a liquid chromatography tandem mass spectrometric method that is in routine clinical use (Quest Diagnostics, Nichols Institute, Chantilly, Va) to determine exposure to tobacco. For additional description of urinary cotinine, see the Methods section in this article's Online Repository at www.jacionline.org.
CD4 T cells, CD8 T cells, eosinophils, and HIV viral load
We assessed CD4 and CD8 T-cell percentages and absolute CD4 T-cell counts in both HIV-infected and HEU participants and HIV-1 RNA viral load in HIV-infected participants at 64 months of the time of the PFT test. 17 We also determined absolute eosinophil counts for HIV-infected and HEU youth within the above time frame.
Covariates
Covariates included age at the time of the PFT examination or at questionnaire if no PFT was performed, race/ethnicity (non-Hispanic white/ other and non-black Hispanics vs blacks regardless of ethnicity), and sex (male vs female).
Data analysis
The distribution of sociodemographic characteristics and pulmonary outcomes was compared across HIV status and PFT categories by using the Wilcoxon rank sum test/Kruskal-Wallis test for continuous variables and the Fisher exact test/Pearson x 2 test for categorical variables. Univariable and multivariable log-binomial regression models were fit to evaluate the associations of HIV status with pulmonary outcomes, including ever asthma (yes/no), current asthma (yes vs not current or never), obstructive versus normal PFT result, restrictive versus normal PFT result, and reversibility after bronchodilation (yes/no). Among those with obstructive disease/normal PFT results, we explored the relationship between HIV status and reversibility using a modified Poisson regression approach. 39 The log-binomial and modified Poisson regression were used to estimate prevalence rate ratios (95% CIs) for current outcomes and risk ratios (95% CIs) for ever asthma for HIV-infected versus HEU participants. We also considered potential effect modification by current asthma and ever asthma on the association between HIV status and outcome reversibility. Multivariable models were adjusted for a priori confounders: age at the time of the PFT examination, race/ethnicity, and sex.
To examine whether the CD4 and CD8 T-cell components might be associated with total nonspecific levels of IgE, we fit a simple linear regression line for each HIV group. In addition, to assess the ability of the IgE immune system to respond to common allergens, we plotted the percentage with high IgE levels (class III response or greater) by HIV status and current asthma.
SAS software (version 9.4; SAS Institute, Cary, NC) was used for all statistical analyses. All statistical tests were 2-sided.
RESULTS
Study population and background characteristics
We enrolled 370 participants (218 HIV-infected and 152 HEU participants) from February 2013 to July 2014. All participants completed at least 1 of the questionnaires, and all but 3 had a PFT examination. Of the 367 with a PFT, the PFT did not meet acceptability criteria for 47 participants (28 [12. 8%] HIV-infected and 19 [12. 5%] HEU participants). Of the 320 (188 HIV-infected and 132 HEU) participants with an evaluable prebronchodilator PFT result, a postbronchodilator PFT was not available for 5 HIV-infected and 6 HEU youth. Of the 320 with evaluable PFT results, pulse oximetry results were obtained for 163 (86.7%) HIV-infected and 120 (90.9%) HEU youth. Table I shows the distribution of background characteristics among the 370 HIV-infected and HEU youth. HIV-infected youth were more likely to be older and identify as black than HEU youth. HIV-infected youth were also more likely to have lower CD4 T-cell counts, higher CD8 T-cell counts, and lower CD4/CD8 T-cell ratios and eosinophil counts than HEU youth (P < .001). They were also more likely to have been exposed to tobacco products. ), but they did not differ in use of montelukast or inhaled corticosteroid. In the subset with at least 1 evaluable PFT, there were no significant differences in FEV 1 or FVC prebronchodilator percent predicted values between HIV-infected and HEU youth. Among those with a prebronchodilator and postbronchodilator PFT, HIV-infected youth were less likely to have reversibility than HEU youth (17/188 [9%] vs 21/132 [17%], P 5 .052). The median for oxygen saturation measured by means of pulse oximetry was 99 (Q1-Q3, 98% to 100%) for both HIV-infected and HEU youth. Table III shows the distribution of characteristics and outcomes by PFT classification sequentially for HIV-infected and HEU youth in unadjusted analyses. We compared those with restrictive and obstructive PFTs with those with normal PFT classifications.
Pulmonary outcomes and medication use by HIV status
Distribution of characteristics and outcomes by PFT categories
HIV-infected youth
Among HIV-infected youth, there were no significant differences in age or race/ethnicity by PFT classification, but those with restrictive disease were less likely to be male than those with normal PFT results (P 5 .041). Those with normal results were less likely to ever have had asthma (31/ , P <.001) results, but none of those with restrictive results had reversibility. The median log HIV-1 RNA viral load was lower in those with normal results compared with those with obstructive results (2.15 vs 1.52, P 5 .002). We observed no significant differences in the distribution of pulse oximetry values, CD4 and CD8 T-cell counts, total serum IgE levels, eosinophil counts, or levels of exposure to tobacco products across PFT groups. However, median CD4/CD8 ratios are higher in those with normal results (0.99) than in those with restrictive (0.72, P 5 .078) or obstructive (0.77, P 5 .058) results.
HEU youth
Among HEU youth, we observed no significant differences in age or sex by PFTs, but those with restrictive results were more likely to identify as non-Hispanic whites/others or nonblack Hispanics and have higher eosinophil counts than those with normal results. Those with obstructive results (13/26 [50%]) were more likely to have reversibility than those with normal results (6/85 [7%]). We observed no significant differences in asthma symptom control, pulse oximetry values, CD8 T-cell counts, total serum IgE levels, and levels of exposure to tobacco products among these groups. However, CD4/CD8 T-cell ratios tended to be higher in those with obstructive (1.78) compared with normal (1.52) results (P 5 .096).
Adjusted associations of pulmonary outcomes with HIV status
The unadjusted and adjusted models for either prevalence ratios (PRs) or risk ratios of pulmonary outcomes in HIV-infected compared with HEU youth are shown in Table IV . We describe the adjusted models (which include age, race/ethnicity, and sex). HIV-infected youth were 53% less likely to have reversibility than HEU youth (PR, 0.47; 95% CI, 0.25-0.89; P 5 .02). Among those with only obstructive classifications, HIV-infected youth were 54% less likely to have reversibility than HEU youth (PR, 0.46; 95% CI, 0.24-0.87; P 5 .016). Among those with a normal PFT result, there was no significant difference in reversibility between HIV-infected and HEU youth. The relationship between HIV status and reversibility did not differ between those with and without current asthma or between those who have ever and those who have never had asthma (interaction term: P 5 .84 and P 5 .12, respectively). When tobacco exposure was added to the above models, the conclusions remained the same.
Total serum IgE levels: Association with CD4 and CD8 T-cell counts, CD4/CD8 ratios, and absolute eosinophil counts in asthmatic youth Among those with current asthma, there was an inverse association between CD4 T-cell counts and total serum IgE levels in HEU youth (regression coefficient [b] 5 20.076 per 100 cells/mL, P 5 .08) but no correlation in HIV-infected youth àParticipants who answered yes to having received a diagnosis of asthma by a physician, having had wheezing at least once since age 3 years, or having received medicine by inhaler or a nebulizer for breathing trouble, wheezing, or coughing in questionnaires were asked a series of questions to determine whether their asthma was under control. §Lymphoid interstitial pneumonia. kDefinition of current asthma medication use in the past year: the participant used an inhaled corticosteroid, or montelukast with albuterol, levalbuterol, or ipratropium in the past year. {A postbronchodilator PFT was not available for 5 HIV-infected and 6 HEU youth. #Of the 370 participants with at least 1 questionnaire completed, pulse oximetry results were obtained for 189 of the 218 HIV-infected youth and 134 of the 152 HEU youth. Of the 320 participants with evaluable prebronchodilator PFT results, pulse oximetry results were obtained for 163 of the 188 HIV-infected youth and 120 of the 132 HEU youth. (b 5 20.026 per 100 cells/mL, P 5 .34; Fig 1, A) . In contrast, we observed an inverse correlation between CD8 T-cell counts and total serum IgE levels in HIV-infected youth (b 5 20.04 per 100 cells/mL, P 5 .03) but none in HEU youth (b 5 0.021 per 100 cells/mL, P 5 .71; Fig 1, B) . There was no association of CD4/CD8 ratios and total serum IgE levels in HIV-infected youth (P 5 6.39 per cells/mL, P 5 .66), but there was an inverse association in HEU youth (b 5 39.25 per cells/ml, P 5 .06; Fig 1, C) . Also, there was a significant positive association between total serum IgE levels and absolute eosinophil counts for HIV-infected youth with current asthma (b 5 0.16 per 100 cells/mm 3 , P 5 .003), whereas no association was found in HEU youth with current asthma (b 5 0.022, P 5 .79; Fig 1, D) .
IgE responses to allergens
In Fig 2 we showed the percentage with high IgE levels by HIV status and current asthma (see Table E4 in this article's Online Repository at www.jacionline.org for values). Several comparisons showed that HIV-infected youth with asthma were less likely to have a class III or higher antibody response to Dermatophagoides pternonyssinus and Dermatophagoides farinae than HEU youth with asthma. Similarly, HIV-infected youth without asthma were less likely to have a class III or higher response to timothy grass, cockroach, peanut, and white oak than HEU youth without asthma.
The eosinophil count was higher in those with D pteronyssinus (house dust mite) class III or higher reactivity than in those with D pteronyssinus class II or lower reactivity among HIV-infected §Participants who answered yes to having received a diagnosis of asthma by a physician, having had wheezing at least once since age 3 years or having received medicine by inhaler, or a nebulizer for breathing trouble, wheezing, or coughing in questionnaires were asked a series of questions to determine whether their asthma was under control. kAmong HIV-infected youth, 4, 2, and 19 participants with restrictive, obstructive, and normal PFT results, respectively, are missing pulse oximetry results. Among HEU youth, 3, 2, and 7 participants with restrictive, obstructive, and normal PFT results, respectively, are missing pulse oximetry results. {CD4 T-cell count data were not available within 4 months of PFT examination for 4 HIV-infected youth with normal PFT results. CD4 T-cell count data were not available within 4 months of PFT examination for 6, 2, and 7 participants with restrictive, obstructive, and normal PFT results, respectively. #Log 10 HIV-1 RNA data were not available within 4 months of PFT examination for 3 HIV-infected youth with normal PFT results. **Total serum IgE data were not available within 4 months of PFT examination for 1 and 3 HIV-infected youth with restrictive and normal PFT results, respectively. Total serum IgE data were not available within 4 months of PFT examination for 6 and 4 HEU youth with restrictive and normal PFT results, respectively. Eosinophil count data were not available within 4 months of PFT examination for 5, 13, and 19 HIV-infected youth with restrictive, obstructive, and normal PFT results, respectively. Eosinophil count data were not available within 4 months of PFT examination for 7, 15, and 39 HEU youth with restrictive, obstructive, and normal PFT results, respectively. ààUrine cotinine data were not available within 4 months of PFT examination for 2, 1, and 7 HIV-infected youth with restrictive, obstructive, and normal PFT results, respectively. Urine cotinine data were not available within 4 months of PFT examination for 5, 1, and 6 HEU youth with restrictive, obstructive, and normal PFT results, respectively. CL, Confidence limit; RR, relative risk. *Unadjusted models estimate the PR/relative risk of pulmonary outcomes in HIV-infected versus HEU adolescents. Relative risk was obtained for ''ever had asthma,'' whereas the PR was obtained for all other pulmonary outcomes. Adjusted models estimate the association between pulmonary outcomes and HIV status when adjusted for age, race/ethnicity, and sex. àModel fit using log-binomial regression approach. §Model fit using the modified Poisson regression approach. kEstimate for the interaction term.
youth with current asthma (P 5 .18) and without current asthma (P < .001, see Table E5 in this article's Online Repository at www.jacionline.org). Eosinophil counts were not significantly different between those with and without reversibility among HIV-infected youth (data not shown).
DISCUSSION
Using several well-accepted criteria for asthma based on family history, physician's diagnosis, and asthma medication use, 2,6,15,17 we found a higher prevalence of asthma in HIVinfected versus HEU youth, as previously observed. 13, 15, 17 Assessment of pulmonary function and bronchodilator response revealed that despite the higher prevalence in HIV-infected youth, they were less likely than HEU youth to demonstrate reversibility. This observation raises doubts as to the accuracy of clinical diagnosis alone in this population. The findings suggest that respiratory signs and symptoms in HIV-infected youth are more likely to be labeled as asthma and treated with asthma medication than in those who are uninfected. These results in youth are consistent with those of Gingo et al, 6 who reported a lack of reversibility in HIV-infected adults given a diagnosis of asthma.
The prevalence of asthma in HEU youth is higher than in the general population but not as high as has been reported in some inner-city minority populations. 40, 41 Some HEU children with airway obstruction did not demonstrate reversibility. This might indicate that maternal HIV infection affected fetal lung tissue or is related to medications taken during pregnancy. Inflammatory mediators and HIV drugs could cross the placenta, injure the developing lung, and create diffuse chronic inflammation. The neonatal HEU group studied by Colin et al 42 demonstrated an unexpected mean 20% decrease in expiratory airflow in HEU neonates compared with age-matched neonatal control participants, which supports the possibility that maternal factors can adversely affect the fetal lung. However, in the absence of a control group without exposure to maternal HIV in utero, we are unable to conclude from our data that HEU youth have a higher prevalence of fixed airway obstruction than healthy adolescents or that they have a higher risk for lung disease in the future.
Studies of the childhood origins of COPD outside the HIV context support the possibility of early immune injury to the lung, causing future immune dysregulation. 43, 44 Infectious viral, bacterial, or fungal pathogens could lodge in the lung and intensify the level of inflammation with recruitment of activated Relationship between patient immune cells and total serum IgE. A, Scatterplot of CD4 T-cell counts and log 10 total serum IgE levels by HIV status among youth with current asthma. B, Scatterplot of CD8 T-cell counts and log 10 total serum IgE levels by HIV status among youth with current asthma. C, Scatterplot of CD4/CD8 ratios and log 10 total serum IgE levels by HIV status among those with current asthma. D, Scatterplot of eosinophil counts and log 10 total serum IgE levels by HIV status among youth with current asthma.
CD4 and CD8 T cells and eosinophils. This mechanism of early lung injury would apply to HIV-infected neonates as well, in whom the scenario of chronic inflammation of lung tissue is even more likely.
The finding that HIV-infected youth have more fixed airway obstruction than HEU youth in late childhood/adolescence suggests that HIV infection might be another factor that poses a risk for future respiratory disease or COPD. Longitudinal studies of lung function in healthy infants 44 and patients with asthma 45, 46 conclusively show that low pulmonary function in early childhood does not correct over time. Hence there is possibility that our study population, who are showing symptoms and reduced PFT in late childhood/adolescence, might represent the sequelae of infants that started with PFT deficits in early life. 47, 48 Our findings raise the possibility that abnormal lung function in early life constitutes an increased risk for lung morbidity in later life in the same way that other conditions associated with decreased pulmonary function in early life predispose such participants to a worse long-term pulmonary outcome. 49 It is also intriguing to speculate that HEUs who have deficits in lung function are at risk of COPD in the future, a question that should be further studied longitudinally.
Our investigation of the possible role of immune imbalance of the asthma-COPD role in HIV-infected and HEU participants is revealing. The IgE system is a protective mechanism against parasitic and fungal infection but also serves as a signal for allergic diseases, such as allergic rhinitis, atopic dermatitis, and asthma. IgE responses to common allergens provide sensitive assessments of abnormal immune control, such as those seen in patients with primary hyper-IgE syndrome 50 or abnormal B-cell switching to IgE production. 51 In our study CD4 T-cell counts were not associated with increasing serum IgE levels, but CD8 T-cell counts were inversely correlated with total serum IgE levels. The lack of CD4 T-cell correlation and the inverse correlation of CD8 T-cell counts with total serum IgE levels supports the concept of the T H 1/T H 2 T-cell imbalance. Also, the strong positive association of absolute eosinophil counts and total serum IgE levels possibly indicates an immune response shifting from a T H 1 cytotoxic and inflammatory response (IFN-g and IL-2) to an altered IgE T H 2 response (IL-4, IL-13, and IL-5 [eosinophil growth factor]).
In conclusion, our study might have uncovered a new pulmonary complication of perinatal HIV infection that begins in infancy, is detected in adolescence, and possibly causes progressive loss of pulmonary health. The finding of nonreversible obstructive lung disease needs to be studied over time so that the importance of lung function trajectory can be better understood in this vulnerable population.
We thank the children and families for their participation in PHACS and the subjects and institutions involved in the conduct of PHACS.
Clinical implications: HIV-infected youth are less likely to demonstrate reversibility on PFTs, suggesting that the clinical symptoms might reflect an early stage of chronic obstructive lung disease rather than typical asthma. Immune dysfunction of CD4 T cells (T H 2 immune imbalance) can influence total nonspecific and specific serum IgE levels.
INTRODUCTION
This report used 2 methods to establish a diagnosis of immune dysfunction for possible immune imbalance: (1) linear regression analysis for the association of CD4 and CD8 T-cell counts with total serum IgE levels, for example, and (2) specific IgE binding to common allergens. Both tests have been used in the literature cited below. The terms ''immunodysregulation, immune dysfunction, [and] immune imbalance'' have been used to describe the immune relationship in patients with HIV infection and atopic disease (atopic dermatitis) and asthma in the literature cited below.
E1-E13
METHODS
Total and specific IgE measurements
Serum samples stored at 2708C were thawed, mixed well, and assayed in batches by using the ImmunoCAP 1000 instrument. Quantitative total and specific IgE levels were reported as kilounits per liter. We assessed levels that were within 4 months of the PFT test, except when considering the distribution of specific IgE levels by HIV and current asthma status where we used all available IgE data. High levels of IgE for each specific allergen were defined as those with a class III or higher IgE level (> _1.4 kU/L).
Urine cotinine
Based on the observed urinary levels of nicotine and its metabolites and the related alkaloid anabasine level, tobacco exposure status was classified as follows: (1) active tobacco use; (2) active tobacco and/or active nicotine replacement use; (3) passive tobacco exposure; (4) no tobacco exposure; and (5) unclassifiable (see http://www.questdiagnostics.com/ testcenter/TestDetail.action?ntc590982). In the present analyses we assessed the distribution of the level of exposure to tobacco products: active (categories 1 and 2), passive (category 3), and no exposure (category 4). Unclassifiable exposure was classified as missing.
TABLE E1. Definition of asthma
Asthma ever, as defined using questionnaires and asthma diagnosis identified using MedDRA Yes If yes, to:
Having received a diagnosis of asthma by a physician (yes to physician diagnosed asthma in or having asthma diagnosis identified by using MedDRA) AND Having had wheezing at least once since age 3 y (from questionnaires) AND Having received medicine through an inhaler or nebulizer for breathing trouble, wheezing, or coughing (from questionnaires).
Current asthma, as defined by using questionnaires and asthma diagnosis identified using MedDRA Yes If yes to:
Having received a diagnosis of asthma by a physician (yes to physician-diagnosed asthma or having asthma diagnosis identified by using MedDRA) AND > _1 asthma sign/symptom in the past 12 months, such as having: wheezing; used albuterol, levalbuterol, or ipratropium; > _1 wheezing/whistling attack; > _1 hospital visit for wheezing/whistling; missing >8 days of work or school because of wheezing OR If no to:
Having received a diagnosis of asthma by a physician BUT Yes to > _2 asthma signs/symptoms in the past 12 months, such as having: wheezing; using albuterol, levalbuterol, or ipratropium; > _1 wheezing/whistling attack; > _1 hospital visit for wheezing/whistling; missing >8 days of work or school because of wheezing OR If yes to:
Having used medication for asthma in the past year Yes if they are using montelukast and albuterol/levalbuterol/ipratropium OR yes if they are using an inhaled corticosteroid; OR If yes to:
Having some more aggressive asthma signs/symptoms, such as having: > _2 wheezing/whistling attacks, OR > _2 hospital visits for wheezing/whistling; OR If yes to:
Still having asthma now, AND Having > _1 asthma sign/symptom in the past 12 months: wheezing; using albuterol, levalbuterol, or ipratropium; MedDRA: any respiratory outcome *These medications are included as a sign/symptom of asthma. These medications are not indicated in definitions for current use of asthma medication. àParticipants are considered to be currently using asthma medication if they are using montelukast and albuterol/levalbuterol/ipratropium or an inhaled corticosteroid.
§Combinations of inhaled corticosteroids with long acting b-agonists. 
